Sugi Predict

Sugi Predict / Compounds / SCHEMBL10273087

SCHEMBL10273087

SCHEMBL10273087

O=c1n(C2CCNCC2)cc(-c2ccnc(N[C@H]3CC[C@H](O)CC3)c2)n1-c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 7/20 0.55
▸ MAPK8 P45983 4/20 0.44
▸ MAPK9 P45984 4/20 0.44
▸ MAPK10 P53779 3/20 0.44
▸ EGFR P00533 1/20 0.39
▸ RAF1 P04049 1/20 0.39
▸ ERBB2 P04626 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ PRKD1 Q15139 6/20 0.39
▸ PRKD2 Q9BZL6 5/20 0.39
▸ ADRB1 P08588 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ CDC7 O00311 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10273091 0.80 MAPK14 (0.42) MAPK14MAPK9KDRPRKD2MAPK1
SCHEMBL10273353 0.75 MAPK9 (0.42) MAPK14MAPK8MAPK9MAPK10EGFR
SCHEMBL13003262 0.73 MAPK14 (0.44) MAPK14MAPK8MAPK9MAPK10
SCHEMBL13003254 0.72 MAPK14 (0.44) MAPK14MAPK8MAPK9MAPK10MAPK1
SCHEMBL765896 0.70 AXL (0.55) MAPK14MAPK8MAPK10
SCHEMBL10273983 0.70 MET (0.43) MAPK14MAPK10
SCHEMBL13376615 0.66 MAPK1 (0.49) MAPK14MAPK8MAPK9MAPK10PRKD2
SCHEMBL5447990 0.66 MAPK14 (0.67) MAPK14MAPK8MAPK9EGFRRAF1
SCHEMBL5447998 0.66 MAPK14 (0.67) MAPK14MAPK8MAPK9EGFRRAF1
SCHEMBL13376763 0.66 IKBKB (0.47) MAPK14MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1439174-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 — — EP disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS OR10J3, NR4A3, NR3C2 MAPK14 2186/4885MAPK8 2163/4885MAPK9 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.